Septerna: Bringing next-generation drug discovery to GPCRs

Building on the research of GPCR pioneer Robert Lefkowitz, Septerna launched with a $100 million Third Rock-led series A round and a platform that modernizes GPCR drug discovery. 

Interim President and CEO Jeff Finer told BioCentury that Septerna Inc. came together in 2019 because Finer and his colleagues at Third Rock Ventures, and Lefkowitz at Duke University School of Medicine, had the same idea: to create a company that brings next-generation small molecule discovery technologies to G-protein coupled receptors...